05-03-2013

A medulloblastoma is a malignant brain tumor that occurs primarily in children and is currently untreatable. Peter Carmeliet and his team (VIB-KU Leuven) joined forces with scientists at Massachusetts General Hospital in Harvard to study the role of the placental growth factor (PIGF) in the ...

more

26-02-2013

Ablynx and Spirogen Ltd. announced a research collaboration to evaluate the potential of a novel anti-cancer drug conjugate combining Spirogen's proprietary cytotoxic drugs, pyrrolobenzodiazepines (PBD), and associated linker technology, with Nanobodies® generated using Ablynx’s proprietary ...

more

Production facility expected to be fully operational in 2015

26-02-2013

Bone Therapeutics, an international biopharmaceutical company focused on cell therapy products for the treatment of bone diseases, announces that it has secured its future manufacturing requirements, allowing it to produce its unique bone cell therapy products on a commercial scale.Bone ...

more

25-02-2013

Cell therapy is a promising alternative to tissue and organ transplantation for diseases that are caused by death or poor functioning of cells. Considering the ethical discussions surrounding human embryonic stem cells, a lot is expected of the so-called 'induced pluripotent stem cells' (iPS ...

more

07-01-2013

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Neupro® (rotigotine transdermal patch) for the treatment of Parkinson’s disease (PD) and for the symptomatic treatment of moderate-to-severe idiopathic Restless Legs Syndrome (RLS) in adults. In 2002 Otsuka Pharmaceutical ...

more

04-01-2013

Oncodesign and the Laboratory for Neurobiology and Gene Therapy (LNGT) at the department of neurosciences at the KU Leuven, an academic group exploring the roles of LRRK2 and a-synuclein in Parkinson’s disease headed by Professor Veerle Baekelandt, announced that they have entered into a ...

more

04-01-2013

Astellas Pharma Inc. and UCB S.A. announced that UCB Japan has received marketing approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Cimzia® (certolizumab pegol). Cimzia®, under joint development in Japan, has been approved as a 200 mg syringe for subcutaneous ...

more

04-12-2012

MDxHealth SA announced that it has joined forces with the Ghent University to establish NXTGNT, a new Center in Pharmaco (Epi)genomics.The mission of the Center is to accelerate innovation in personalized medicine by using advanced technology, knowledge and expertise in (epi)genetics. The ...

more

29-11-2012

Abbott announced that the European Commission has approved HUMIRA® (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn's disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy. With this approval, HUMIRA ...

more

First candidate antibiotic is effective against all tested MRSA strains

27-11-2012

Galapagos NV announced that it has discovered an entirely new class of antibiotics. The Company has selected a candidate drug that shows strong activity against all tested drug resistant Staphylococcus aureus, including hospital and community acquired MRSA strains.Bacterial infections that ...

more